A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM). Study will compare four dose combinations of empagliflozin + metformin versus each individual component after 24 weeks of treatment.
Inclusion criteria:
Exclusion criteria:
Abbasia Cairo, Egypt, Egypt
El Darasa Cairo Egypt, Egypt
Vandome, France
Stuhr-Brinkum, Germany
Barbena Santa Rosa, Guatemala
El Chouf, Lebanon
Ipoh, Perak, Malaysia
San Lucas Tepetlcalco, Mexico
Cebu City, Cebu, Philippines
Cebu City, Philippines, Philippines
Maybunga, Pasig City, Philippines
Deagu, South Korea